Biosimilar for Infliximab Launched in Europe

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Celltrion launches world’s first biosimilar monoclonal antibody Remsima in 12 new European markets. First Word Pharma. 2015 Feb 24.
2. FDA delays meeting to evaluate infliximab biosimilar. GABI Online. 2015 Feb. 27.
3. CymaBay Therapeutics announces positive results from its Phase 2b clinical study demonstrating that arhalofenate met the primary endpoint of reduction in gout flares. CymaBay Therapeutics. 2015 Feb 24.
4. Pfizer announces FDA acceptance for review of a new drug application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride). Pfizer. 2015 Feb 13.
5. Baricitinib superior to placebo in reducing rheumatoid arthritis disease activity in second Phase 3 study. Eli Lilly & Co. 2015 Feb 23.
6. Arthritis drug baricitinib meets primary endpoint in Phase 3 RA_BEACON study. News Medical. 2014 Dec 9.
7. Walsh N. JAK-3 drug effective in RA, but safe? MedPageToday. 2015 Feb 12.